Breaking News Instant updates and real-time market news.

PCRX

Pacira

$31.40

-1.45 (-4.41%)

07:46
11/29/16
11/29
07:46
11/29/16
07:46

Pacira, GeneAlign announce partnership for low-opioid pain management protocols

Pacira Pharmaceuticals announced a joint endeavor with GeneAlign, a therapeutic management and solutions company. Under the collaborative research partnership, a GeneAlign scientific team will work alongside a Pacira team to develop and utilize these survey tools and genetic testing assets to identify preoperative patients with genetic markers indicating a potential predisposal to opioid addiction.This hospital-based initiative is currently being rolled out in pilot institutions and includes a GeneAlign genetic test conducted via a quick and painless cheek swab that collects information on 19 genes associated with metabolism, clinical response and addiction risk. The test provides important information regarding the patient's genetic predisposition to numerous commonly prescribed opioids and other non-opioid drugs relevant to the perioperative setting. Additionally, this comprehensive program provides patients with education about the risks and benefits associated with opioid and non-opioid pain medications, including the potential for opioid addiction. The patient's attending clinicians will then have access to this information to assist them in the development of individualized postsurgical pain management strategies following evidence-based protocols.

  • 29

    Nov

PCRX Pacira
$31.40

-1.45 (-4.41%)

10/07/16
BMUR
10/07/16
INITIATION
BMUR
Hold
Pacira coverage assumed with a Hold at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage on Pacira with a Hold rating while the company builds out its clinical case and expands its Exparel label.
10/26/16
BMOC
10/26/16
UPGRADE
BMOC
Market Perform
Pacira upgraded to Market Perform from Underperform at BMO Capital
10/26/16
BMOC
10/26/16
UPGRADE
Target $35
BMOC
Market Perform
Pacira upgraded to Market Perform from Underperform at BMO Capital
BMO Capital analyst Gary Nachman upgraded Pacira Pharmaceuticals to Market Perform saying the risk/reward is more balanced now that expectations have been reduced. The analyst sees more limited downside risk and lowered his price target for the shares to $35 from $36.
11/23/16
BMOC
11/23/16
NO CHANGE
Target $35
BMOC
Market Perform
Pacira sales of Exparel continue to struggle, says BMO Capital
According to Symphony data released today, October sales of Pacira Pharmaceuticals' Exparel were $20.2M, down 12% year-over-year and down 9% month-over-month, BMO Capital analyst Gary Nachman tells investors in a research note. The analyst views the number as "not a great start" to Q4 and thinks Pacira may be challenged to hit the low end of its $263M-$268M Exparel sales guidance. He keeps a Market Perform rating on the shares with a $35 price target. Pacira is down 8%, or $2.75, to $31.60 in late morning trading.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.